Investigational glucagon receptor antagonists in Phase I and II clinical trials for diabetes
出版年份 2017 全文链接
标题
Investigational glucagon receptor antagonists in Phase I and II clinical trials for diabetes
作者
关键词
-
出版物
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 26, Issue 12, Pages 1373-1389
出版商
Informa UK Limited
发表日期
2017-10-20
DOI
10.1080/13543784.2017.1395020
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Insulin and Glucagon: Partners for Life
- (2017) Jens Juul Holst et al. ENDOCRINOLOGY
- Population pharmacokinetics and pharmacodynamics of IONIS-GCGRRx, an antisense oligonucleotide for type 2 diabetes mellitus: a red blood cell lifespan model
- (2017) Kenneth T. Luu et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- The New Biology and Pharmacology of Glucagon
- (2017) T. D. Müller et al. PHYSIOLOGICAL REVIEWS
- Glucagon receptor inhibition normalizes blood glucose in severe insulin-resistant mice
- (2017) Haruka Okamoto et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Glucagon antagonism in islet cell proliferation
- (2017) E. Danielle Dean et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Response to Comment on The Look AHEAD Research Group. Prospective Association of GLUL rs10911021 With Cardiovascular Morbidity and Mortality Among Individuals With Type 2 Diabetes: The Look AHEAD Study. Diabetes 2016;65:297–302
- (2016) Jeanne M. McCaffery et al. DIABETES
- Clinical Trials, Triumphs, and Tribulations of Glucagon Receptor Antagonists
- (2016) Mackenzie J. Pearson et al. DIABETES CARE
- Pharmacokinetics and pharmacodynamics of single and multiple doses of the glucagon receptor antagonist LGD-6972 in healthy subjects and subjects with type 2 diabetes mellitus
- (2016) Eric G. Vajda et al. DIABETES OBESITY & METABOLISM
- Effects of multiple ascending doses of the glucagon receptor antagonist PF-06291874 in patients with type 2 diabetes mellitus
- (2016) D. J. Kazierad et al. DIABETES OBESITY & METABOLISM
- Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates
- (2016) S. J. Henderson et al. DIABETES OBESITY & METABOLISM
- Glucagon therapeutics: Dawn of a new era for diabetes care
- (2016) Jaime A. Davidson et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Glucagon action in the brain
- (2016) Mona A. Abraham et al. DIABETOLOGIA
- Glucagon is the key factor in the development of diabetes
- (2016) Young H. Lee et al. DIABETOLOGIA
- THE ROLE OF GLUCAGON IN THE PATHOPHYSIOLOGY AND MANAGEMENT OF DIABETES
- (2016) Georgia R. Kulina et al. Endocrine Practice
- Investigational insulin secretagogues for type 2 diabetes
- (2016) André J. Scheen EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Blockade of glucagon signaling prevents or reverses diabetes onset only if residual β-cells persist
- (2016) Nicolas Damond et al. eLife
- Future glucose-lowering drugs for type 2 diabetes
- (2016) Clifford J Bailey et al. Lancet Diabetes & Endocrinology
- Glucagon receptor gene deletion in insulin knockout mice modestly reduces blood glucose and ketones but does not promote survival
- (2016) Ursula H. Neumann et al. Molecular Metabolism
- Landmark studies on the glucagon subfamily of GPCRs: from small molecule modulators to a crystal structure
- (2015) De-hua Yang et al. ACTA PHARMACOLOGICA SINICA
- Recent progress in the development of small-molecule glucagon receptor antagonists
- (2015) Matthew F. Sammons et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies
- (2015) Christof M. Kazda et al. DIABETES CARE
- Short-term administration of the glucagon receptor antagonist LY2409021 lowers blood glucose in healthy people and in those with type 2 diabetes
- (2015) R. P. Kelly et al. DIABETES OBESITY & METABOLISM
- Inhibiting or antagonizing glucagon: making progress in diabetes care
- (2015) P. J. Lefèbvre et al. DIABETES OBESITY & METABOLISM
- Acute disruption of glucagon secretion or action does not improve glucose tolerance in an insulin-deficient mouse model of diabetes
- (2015) Vivi R. Steenberg et al. DIABETOLOGIA
- Glucagon Receptor Blockade With a Human Antibody Normalizes Blood Glucose in Diabetic Mice and Monkeys
- (2015) Haruka Okamoto et al. ENDOCRINOLOGY
- Discontinued drug therapies to treat diabetes in 2014
- (2015) Jerry R Colca EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Small molecule glucagon receptor antagonists: a patent review (2011 – 2014)
- (2015) Kevin J Filipski EXPERT OPINION ON THERAPEUTIC PATENTS
- Glucagon Cell Hyperplasia and Neoplasia With and Without Glucagon Receptor Mutations
- (2015) Bence Sipos et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Lack of glucagon receptor signaling and its implications beyond glucose homeostasis
- (2015) M. J. Charron et al. JOURNAL OF ENDOCRINOLOGY
- Glucagon receptor antagonism induces increased cholesterol absorption
- (2015) Hong-Ping Guan et al. JOURNAL OF LIPID RESEARCH
- A new paradigm for treating obesity and diabetes mellitus
- (2015) André J. Scheen et al. Nature Reviews Endocrinology
- Islet α cells and glucagon—critical regulators of energy homeostasis
- (2015) Jonathan E. Campbell et al. Nature Reviews Endocrinology
- Glucagon – Early breakthroughs and recent discoveries
- (2015) Bo Ahrén PEPTIDES
- Glucagon receptor antibody completely suppresses type 1 diabetes phenotype without insulin by disrupting a novel diabetogenic pathway
- (2015) May-Yun Wang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A Semi-mechanistic Model for the Effects of a Novel Glucagon Receptor Antagonist on Glucagon and the Interaction Between Glucose, Glucagon, and Insulin Applied to Adaptive Phase II Design
- (2014) Joanna Z. Peng et al. AAPS Journal
- Two novel glucagon receptor antagonists prove effective therapeutic agents in high-fat-fed and obese diabetic mice
- (2014) F. P. M. O'Harte et al. DIABETES OBESITY & METABOLISM
- Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus
- (2014) André J. Scheen DRUGS
- Characterization of a Standardized Glucagon Challenge Test as a Pharmacodynamic Tool in Pharmacological Research
- (2014) M.G. van Dongen et al. HORMONE AND METABOLIC RESEARCH
- First proof of pharmacology in humans of a novel glucagon receptor antisense drug
- (2014) Marloes G. J. van Dongen et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Ablation of glucagon receptor signaling by peptide-based glucagon antagonists improves glucose tolerance in high fat fed mice
- (2014) Laura M. McShane et al. PEPTIDES
- The design and synthesis of a potent glucagon receptor antagonist with favorable physicochemical and pharmacokinetic properties as a candidate for the treatment of type 2 diabetes mellitus
- (2013) Angel Guzman-Perez et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Fibroblast Growth Factor 21 (FGF21) and Glucagon-Like Peptide 1 Contribute to Diabetes Resistance in Glucagon Receptor-Deficient Mice
- (2013) B. A. Omar et al. DIABETES
- Pancreatic α-Cell Hyperplasia: Facts and Myths
- (2013) Run Yu JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Characterisation of structurally modified analogues of glucagon as potential glucagon receptor antagonists
- (2013) F.P.M. O’Harte et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Structure of the human glucagon class B G-protein-coupled receptor
- (2013) Fai Yiu Siu et al. NATURE
- Expression, purification and preliminary characterization of glucagon receptor extracellular domain
- (2013) Lili Wu et al. PROTEIN EXPRESSION AND PURIFICATION
- Liver-Specific Disruption of the Murine Glucagon Receptor Produces -Cell Hyperplasia: Evidence for a Circulating -Cell Growth Factor
- (2012) C. Longuet et al. DIABETES
- Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover
- (2012) Roger H. Unger et al. JOURNAL OF CLINICAL INVESTIGATION
- Discovery of a Novel Glucagon Receptor Antagonist N-[(4-{(1S)-1-[3-(3, 5-Dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl]ethyl}phenyl)carbonyl]-β-alanine (MK-0893) for the Treatment of Type II Diabetes
- (2012) Yusheng Xiong et al. JOURNAL OF MEDICINAL CHEMISTRY
- Polyomic profiling reveals significant hepatic metabolic alterations in glucagon-receptor (GCGR) knockout mice: implications on anti-glucagon therapies for diabetes
- (2011) Jianxin Yang et al. BMC GENOMICS
- Hepatic Glucagon Action Is Essential for Exercise-Induced Reversal of Mouse Fatty Liver
- (2011) Eric D. Berglund et al. DIABETES
- Novel insight into glucagon receptor action: lessons from knockout and transgenic mouse models
- (2011) P. M. Vuguin et al. DIABETES OBESITY & METABOLISM
- Early milestones in glucagon research
- (2011) P. J. Lefèbvre DIABETES OBESITY & METABOLISM
- Glucagon antagonism as a potential therapeutic target in type 2 diabetes
- (2011) J. I. Bagger et al. DIABETES OBESITY & METABOLISM
- Chronic treatment with a glucagon receptor antagonist lowers glucose and moderately raises circulating glucagon and glucagon-like peptide 1 without severe alpha cell hypertrophy in diet-induced obese mice
- (2011) J. Mu et al. DIABETOLOGIA
- A survey of small molecule glucagon receptor antagonists from recent patents (2006 – 2010)
- (2011) Dong-Ming Shen et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Dual elimination of the glucagon and GLP-1 receptors in mice reveals plasticity in the incretin axis
- (2011) Safina Ali et al. JOURNAL OF CLINICAL INVESTIGATION
- Fully Human Monoclonal Antibodies Antagonizing the Glucagon Receptor Improve Glucose Homeostasis in Mice and Monkeys
- (2009) H. Yan et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Long-Term Inhibition of the Glucagon Receptor with a Monoclonal Antibody in Mice Causes Sustained Improvement in Glycemic Control, with Reversible -Cell Hyperplasia and Hyperglucagonemia
- (2009) W. Gu et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Homozygous P86S Mutation of the Human Glucagon Receptor Is Associated With Hyperglucagonemia, α Cell Hyperplasia, and Islet Cell Tumor
- (2009) Cuiqi Zhou et al. PANCREAS
- Benefits and limitations of reducing glucagon action for the treatment of type 2 diabetes
- (2008) Safina Ali et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- The Glucagon Receptor Is Required for the Adaptive Metabolic Response to Fasting
- (2008) Christine Longuet et al. Cell Metabolism
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started